A Spot of Selling at Liquidia

by

It appears Opaleye Management Inc., a firm with a name that conjures images of particularly discerning fish, has seen fit to lighten its holdings in Liquidia, a company engaged in the rather vital business of keeping one’s pulmonary arteries in tip-top shape. A sale of some 180,000 shares, amounting to a tidy $5.12 million, occurred during the fourth quarter of last year, according to a filing with the Securities and Exchange Commission. One gathers they’ve decided a bit less Liquidia is precisely the thing for their portfolio, a decision which, while perhaps not catastrophic, is certainly worth a moment’s consideration.

The fund, it seems, still holds a substantial chunk – some 2,435,000 shares, to be precise – and the overall value of their stake actually increased during the period, by a respectable $25.52 million. This curious state of affairs is due, of course, to a combination of factors: the aforementioned sale, naturally, but also the stock’s rather spirited performance. It’s a bit like trimming the herbaceous border while the roses continue to bloom, don’t you agree?

As of the latest reckoning, Liquidia now accounts for approximately 11.21% of Opaleye’s reportable assets under management. A significant slice of the pie, certainly, but perhaps not quite as large as it once was. One suspects the chaps at Opaleye are merely ensuring a bit of diversification, a prudent course of action for any investor with a modicum of sense.

Their top holdings, for the curious, are as follows: HROW, commanding a substantial $191.34 million; Liquidia itself, at $84.98 million; ETON, with $48.36 million; RYTM, at $35.32 million; and APGE, bringing up the rear with $29.31 million. A perfectly respectable assortment, one might say, though whether it’s a recipe for unmitigated success remains to be seen.

Now, the stock itself, as of February 17th, was trading at $33.84, a most agreeable price, and has enjoyed a rather remarkable run over the past year, climbing a full 105.7%. It’s left the S&P 500 trailing in its wake, by a margin of 97.0 percentage points. A performance that would give even the most seasoned investor cause for a cheerful grin.

A Brief Word on the Company

Liquidia, for those unfamiliar, is a biopharmaceutical firm specializing in therapies for pulmonary arterial hypertension. They’ve concocted a rather ingenious inhaled dry powder formulation of treprostinil, marketed as YUTREPIA, and also distribute a generic version of treprostinil injection. Their revenue, it seems, is primarily derived from developing, manufacturing, and commercializing these treatments, addressing a rather pressing medical need.

They target healthcare providers and patients in the United States, offering advanced therapies for pulmonary arterial hypertension and related conditions. A noble pursuit, one must say, and one that, if executed with sufficient competence, is bound to yield a handsome return.

The company’s competitive advantage, if one may be so bold, lies in its specialized expertise in inhaled drug delivery and its ability to commercialize both branded and generic therapies within a sector renowned for its complexity and regulation.

What Does This All Mean for the Average Investor?

Now, one might ask, what is the upshot of all this for the chap in the street? Well, it’s a bit like this: Liquidia is a pharmaceutical stock, dealing with treatments for high blood pressure, specifically through inhalable medicine. The pharmaceutical industry, as anyone with a passing acquaintance with the subject will tell you, is a positively labyrinthine affair. There are giants and minnows, private companies and public ones, and a regulatory framework so dense it would make a seasoned bureaucrat weep.

Navigating this terrain requires a certain degree of expertise, and frankly, for the average investor, it can be a bit like trying to thread a needle in a hurricane. Therefore, in my humble opinion, the best course of action is to turn to exchange-traded funds – ETFs. By spreading one’s exposure across a wide array of stocks in the industry, one gains a degree of protection against the vagaries of fate, and the possibility of a single company’s fortunes taking a downturn.

It’s a bit like having a diversified portfolio of umbrellas, rather than relying on a single, rather flimsy specimen. A prudent strategy, wouldn’t you agree? In short, a little bit of diversification goes a long way towards ensuring a peaceful night’s sleep.

Metric Value
Price (as of market close 2/17/26) $33.84
Market capitalization $2.94 billion
Revenue (TTM) $69.22 million
Net income (TTM) ($121.85 million)

Read More

2026-03-04 18:52